View Older Stories View More Recent Stories

Aug 5, 2022 08:30AM Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022
Aug 4, 2022 04:01PM Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board
Jun 4, 2022 01:40PM Legend Biotech (LEGN) Reports Long-Term Data from CARTITUDE Program Shows Deep and Durable Responses with Ciltacabtagene Autoleucel
Jun 4, 2022 09:00AM Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma
Jun 3, 2022 08:31AM Legend Biotech (LEGN) Granted FDA Clearance of IND for LB1908
Jun 3, 2022 08:30AM Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers
Jun 1, 2022 08:30AM Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights
May 31, 2022 04:01PM Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 05:38AM Legend Biotech (LEGN) Announces CARVYKTI Granted Conditional Approval in EU for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 26, 2022 03:10AM CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
May 18, 2022 08:30AM Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
May 9, 2022 06:30AM Legend Biotech (LEGN) Appoints Lori Macomber as CFO
May 9, 2022 06:30AM Legend Biotech Appoints Lori Macomber as Chief Financial Officer
May 6, 2022 04:01PM Legend Biotech Announces Participation in Upcoming Investor Conferences
Apr 21, 2022 08:32AM Legend Biotech (LEGN) Achieves $50M Milestone Under Collaboration Agreement with Janssen Biotech for BCMA
Apr 21, 2022 08:30AM Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T
Apr 1, 2022 04:09PM Legend Biotech (LEGN) Announces Appointment of Global Head of Research and Early Development
Apr 1, 2022 04:01PM Legend Biotech Announces Appointment of Global Head of Research and Early Development
Mar 25, 2022 08:01AM CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Mar 25, 2022 07:54AM Johnson & Johnson (JNJ) Announces Positive CHMP Opinion Recommending CARVYKTI for Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Mar 25, 2022 07:50AM  Janssen Receives Positive CHMP Opinion Recommending CARVYKTI® (Ciltacabtagene Autoleucel) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Mar 23, 2022 08:30AM Flanders Investment and Trade Names Legend Biotech Newcomer of the Year
Mar 18, 2022 04:02PM Legend Biotech (LEGN) Reports Q4 Results
Mar 18, 2022 04:01PM Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
Mar 1, 2022 05:57AM Legend Biotech's (LEGN) CARVYKTI Approved by FDA for Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Feb 28, 2022 09:20PM CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Feb 28, 2022 08:48PM U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Feb 18, 2022 08:31AM Legend Biotech (LEGN) Reports Prelim 2021 Results
Feb 18, 2022 08:30AM Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
Feb 15, 2022 08:32AM Legend Biotech (LEGN) Announces FDA Clinical Hold of Phase 1 Clinical Trial for LB1901
Feb 15, 2022 08:30AM Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
Feb 11, 2022 08:30AM Legend Biotech (LEGN) Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
Feb 11, 2022 08:30AM Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
Jan 4, 2022 08:30AM Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 09:04AM Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye
Dec 13, 2021 09:00AM Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
Dec 12, 2021 04:37PM New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma
Dec 7, 2021 09:36AM Legend Biotech (LEGN) Announces Submission of NDA to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Dec 7, 2021 09:36AM Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Dec 7, 2021 08:30AM Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 6, 2021 08:31AM Legend Biotech (LEGN) Announces Submission of NDA to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of R/R Multiple Myeloma by Janssen
Dec 6, 2021 08:30AM Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Nov 16, 2021 08:30AM Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
Nov 4, 2021 08:34AM Legend Biotech (LEGN) Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
Nov 4, 2021 08:30AM Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
Nov 1, 2021 04:00PM Legend Biotech (LEGN) Announces Extension of PDUFA Date for Cilta-Cel
Nov 1, 2021 04:00PM Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
Jun 1, 2021 08:12AM Legend Biotech (LEGN) Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and
Jun 1, 2021 08:11AM Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
Jun 1, 2021 08:00AM Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Mee
View More Recent Stories View Older Stories